Drug-Induced Thrombocytopenia

Hematology/Oncology Clinics of North America

Volumn 21, Issue 4, 2007, Pages 685-696

  Visentin, Gian Paolo ^a,b   Liu, Chao Yan ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; AGRASTAT; ALCOHOL; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT; BLEOMYCIN; CD31 ANTIGEN; CINCHONA ALKALOID; DIURETIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GOLD SALT; HAPTEN ANTIBODY; HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PENICILLIN DERIVATIVE; PROCAINAMIDE; QUINIDINE; QUININE; RANITIDINE; RIFAMPICIN; ROXIFIBAN; SULFONAMIDE; THIAZIDE DIURETIC AGENT; TIROFIBAN; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY COMPLEX; CLINICAL FEATURE; DISEASE SEVERITY; DRUG INDUCED DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNE RESPONSE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; WESTERN BLOTTING;

ANTIBODIES; ANTIBODY FORMATION; HAPTENS; HUMANS; PHARMACEUTICAL PREPARATIONS; THROMBOCYTOPENIA;

EID: 34547114992     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.06.005     Document Type: Review

References (86)

1. Wazny L.D., and Ariano R.E. Evaluation and management of drug-induced thrombocytopenia in the acutely ill patient. Pharmacotherapy 20 (2000) 292-307
2. Rothe G. [Differential diagnosis of platelet disorders]. Dtsch Med Wochenschr 131 (2006) 219-222 [in German]
3. Payne B.A., and Pierre R.V. Pseudothrombocytopenia: a laboratory artifact with potentially serious consequences. Mayo Clin Proc 59 (1984) 123-125
4. Bartels P.C., Schoorl M., and Lombarts A.J. Screening for EDTA-dependent deviations in platelet counts and abnormalities in platelet distribution histograms in pseudothrombocytopenia. Scand J Clin Lab Invest 57 (1997) 629-636
5. Sane D.C., Damaraju L.V., Topol E.J., et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 36 (2000) 75-83
6. Greinacher A., Eichler P., Lubenow N., et al. Drug-induced and drug-dependent immune thrombocytopenias. Rev Clin Exp Hematol 5 (2001) 166-200
7. Bonfiglio M.F., Traeger S.M., Kier K.L., et al. Thrombocytopenia in intensive care patients: a comprehensive analysis of risk factors in 314 patients. Ann Pharmacother 29 (1995) 835-842
8. Shalansky S.J., Verma A.K., Levine M., et al. Risk markers for thrombocytopenia in critically ill patients: a prospective analysis. Pharmacotherapy 22 (2002) 803-813
9. Drews R.E. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients. Clin Chest Med 24 (2003) 607-622
10. Nguyen T.C., Stegmayr B., Busund R., et al. Plasma therapies in thrombotic syndromes. Int J Artif Organs 28 (2005) 459-465
11. Pedersen-Bjergaard U., Andersen M., and Hansen P.B. Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy. Eur J Clin Pharmacol 52 (1997) 183-189
12. Carey P.J. Drug-induced myelosuppression: diagnosis and management. Drug Saf 26 (2003) 691-706
13. Mueller-Eckhardt C., Kuenzlen E., Kiefel V., et al. Cyclophosphamide-induced immune thrombocytopenia in a patient with ovarian carcinoma successfully treated with intravenous gamma globulin. Blut 46 (1983) 165-169
14. Seidman A.D., Schwartz M., Reich L., et al. Immune-mediated thrombocytopenia secondary to suramin. Cancer 71 (1993) 851-854
15. Bozec L., Bierling P., Fromont P., et al. Irinotecan-induced immune thrombocytopenia. Ann Oncol 9 (1998) 453-455
16. Shannon A., Smith J., Nagel K., et al. Selective thrombocytopenia in children with Wilms tumor: an immune-mediated effect of dactinomycin?. Med Pediatr Oncol 41 (2003) 483-485
17. Curtis B.R., Kaliszewski J., Marques M.B., et al. Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol 81 (2006) 193-198
18. Rutherford C.J., and Frenkel E.P. Thrombocytopenia. Issues in diagnosis and therapy. Med Clin North Am 78 (1994) 555-575
19. Majhail N.S., and Lichtin A.E. What is the best way to determine if thrombocytopenia in a patient on multiple medications is drug-induced?. Cleve Clin J Med 69 (2002) 259-262
20. Eisner E.V., and Crowell E.B. Hydrochlorothiazide-dependent thrombocytopenia due to IgM antibody. JAMA 215 (1971) 480-482
21. Aster R.H. Drug-induced immune cytopenias. Toxicology 209 (2005) 149-153
22. Aster R.H. Drug-induced immune thrombocytopenia: an overview of pathogenesis. Semin Hematol 36 (1999) 2-6
23. Chong B.H., Du X.P., Berndt M.C., et al. Characterization of the binding domains on platelet glycoproteins Ib-IX and IIb/IIIa complexes for the quinine/quinidine-dependent antibodies. Blood 77 (1991) 2190-2199
24. Curtis B.R., McFarland J.G., Wu G.G., et al. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood 84 (1994) 176-183
25. Gentilini G., Curtis B.R., and Aster R.H. An antibody from a patient with ranitidine-induced thrombocytopenia recognizes a site on glycoprotein IX that is a favored target for drug-induced antibodies. Blood 92 (1998) 2359-2365
26. Burgess J.K., Lopez J.A., Gaudry L.E., et al. Rifampicin-dependent antibodies bind a similar or identical epitope to glycoprotein IX-specific quinine-dependent antibodies. Blood 95 (2000) 1988-1992
27. van den Bemt P.M., Meyboom R.H., and Egberts A.C. Drug-induced immune thrombocytopenia. Drug Saf 27 (2004) 1243-1252
28. George J.N., Raskob G.E., Shah S.R., et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 129 (1998) 886-890
29. Li X., Swisher K.K., Vesely S.K., et al. Drug-induced thrombocytopenia: an updated systematic review, 2006. Drug Saf 30 (2007) 185-186
30. Brinker A.D., and Beitz J. Spontaneous reports of thrombocytopenia in association with quinine: clinical attributes and timing related to regulatory action. Am J Hematol 70 (2002) 313-317
31. Lee D.H., and Warkentin T.E. Frequency of heparin-induced thrombocytopenia. In: Warkentin T.E., and Greinacher A. (Eds). Heparin-induced thrombocytopenia. 3rd edition (2003), Marcel Dekker, New York 107-148
32. Christie D.J., Mullen P.C., and Aster R.H. Fab-mediated binding of drug-dependent antibodies to platelets in quinidine- and quinine-induced thrombocytopenia. J Clin Invest 75 (1985) 310-314
33. Batchelor F.R., Dewdney J.M., and Gazzard D. Penicillin allergy: the formation of the penicilloyl determinant. Nature 206 (1965) 362-364
34. Weltzien H.U., and Padovan E. Molecular features of penicillin allergy. J Invest Dermatol 110 (1998) 203-206
35. Weltzien H.U., Moulon C., Martin S., et al. T cell immune responses to haptens. Structural models for allergic and autoimmune reactions. Toxicology 107 (1996) 141-151
36. Garratty G. Immune cytopenia associated with antibiotics. Transfus Med Rev 7 (1993) 255-267
37. Murphy M.F., Riordan T., Minchinton R.M., et al. Demonstration of an immune-mediated mechanism of penicillin-induced neutropenia and thrombocytopenia. Br J Haematol 55 (1983) 155-160
38. Salamon D.J., Nusbacher J., Stroupe T., et al. Red cell and platelet-bound IgG penicillin antibodies in a patient with thrombocytopenia. Transfusion 24 (1984) 395-398
39. Kunicki T.J., Russell N., Nurden A.T., et al. Further studies of the human platelet receptor for quinine- and quinine-dependent antibodies. J Immunol 126 (1981) 398-402
40. Berndt M.C., Chong B.H., Bull H.A., et al. Molecular characterization of quinine/quinidine drug-dependent antibody platelet interaction using monoclonal antibodies. Blood 66 (1985) 1292-1301
41. Stricker R.B., and Shuman M.A. Quinidine purpura: evidence that glycoprotein V is a target platelet antigen. Blood 67 (1986) 1377-1381
42. Christie D.J., Mullen P.C., and Aster R.H. Quinine- and quinidine platelet antibodies can react with GPIIb/IIIa. Br J Haematol 67 (1987) 213-219
43. Kroll H., Sun Q.H., and Santoso S. Platelet endothelial cell adhesion molecule-1 (PECAM-1) is a target glycoprotein in drug-induced thrombocytopenia. Blood 96 (2000) 1409-1414
44. Bougie D., and Aster R. Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen. Blood 97 (2001) 3846-3850
45. Burgess J.K., Lopez J.A., Berndt M.C., et al. Quinine-dependent antibodies bind a restricted set of epitopes on the glycoprotein Ib-IX complex: characterization of the epitopes. Blood 92 (1998) 2366-2373
46. Visentin G.P., Newman P.J., and Aster R.H. Characteristics of quinine- and quinidine-induced antibodies specific for platelet glycoproteins IIb and IIIa. Blood 77 (1991) 2668-2676
47. Bougie D.W., Wilker P.R., and Aster R.H. Patients with quinine-induced immune thrombocytopenia have both "drug-dependent" and "drug-specific" antibodies. Blood 108 (2006) 922-927
48. Peterson J.A., Nyree C.E., Newman P.J., et al. A site involving the "hybrid" and PSI homology domains of GPIIIa (beta 3-integrin subunit) is a common target for antibodies associated with quinine-induced immune thrombocytopenia. Blood 101 (2003) 937-942
49. Asvadi P., Ahmadi Z., and Chong B.H. Drug-induced thrombocytopenia: localization of the binding site of GPIX-specific quinine-dependent antibodies. Blood 102 (2003) 1670-1677
50. Aster R.H. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 127 (2005) 53S-59S
51. Huxtable L.M., Tafreshi M.J., and Rakkar A.N. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. Am J Cardiol 97 (2006) 426-429
52. Brassard J.A., Curtis B.R., Cooper R.A., et al. Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology. Thromb Haemost 88 (2002) 892-897
53. Coller B.S. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest 99 (1997) 1467-1471
54. Aster R.H., Curtis B.R., Bougie D.W., et al. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost 4 (2006) 678-679
55. Bougie D.W., Wilker P.R., Wuitschick E.D., et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 100 (2002) 2071-2076
56. Dunkley S., Evans S., Gaudry L., et al. Two distinct subgroups of tirofiban-induced thrombocytopenia exist due to drug dependent antibodies that cause platelet activation and increased ischaemic events. Platelets 16 (2005) 462-468
57. Curtis B.R., Divgi A., Garritty M., et al. Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2 (2004) 985-992
58. Curtis B.R., Swyers J., Divgi A., et al. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 99 (2002) 2054-2059
59. Lerner W., Caruso R., Faig D., et al. Drug-dependent and non-drug-dependent antiplatelet antibody in drug-induced immunologic thrombocytopenic purpura. Blood 66 (1985) 306-311
60. Aster R.H. Can drugs cause autoimmune thrombocytopenic purpura?. Semin Hematol 37 (2000) 229-238
61. dem Borne A.E., Pegels J.G., van der Stadt R.J., et al. Thrombocytopenia associated with gold therapy: a drug-induced autoimmune disease?. Br J Haematol 63 (1986) 509-516
62. Lanzavecchia A. How can cryptic epitopes trigger autoimmunity?. J Exp Med 181 (1995) 1945-1948
63. Sercarz E.E., Lehmann P.V., Ametani A., et al. Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 11 (1993) 729-766
64. Griem P., and Gleichmann E. Metal ion induced autoimmunity. Curr Opin Immunol 7 (1995) 831-838
65. Griem P., Panthel K., Kalbacher H., et al. Alteration of a model antigen by Au(III) leads to T cell sensitization to cryptic peptides. Eur J Immunol 26 (1996) 279-287
66. Takahashi K., Kropshofer H., Vogt A.B., et al. Drug-induced inhibition of insulin recognition by T-cells: the antirheumatic drug aurothiomalate inhibits MHC binding of insulin peptide. Mol Immunol 35 (1998) 1081-1087
67. Romagnoli P., Spinas G.A., and Sinigaglia F. Gold-specific T cells in rheumatoid arthritis patients treated with gold. J Clin Invest 89 (1992) 254-258
68. Simitsek P.D., Campbell D.G., Lanzavecchia A., et al. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J Exp Med 181 (1995) 1957-1963
69. Salemi S., Caporossi A.P., Boffa L., et al. HIVgp120 activates autoreactive CD4-specific T cell responses by unveiling of hidden CD4 peptides during processing. J Exp Med 181 (1995) 2253-2257
70. Croft Jr. J.D., Swisher Jr. S.N., Gilliland B.C., et al. Coombs'-test positivity induced by drugs. Mechanisms of immunologic reactions and red cell destruction. Ann Intern Med 68 (1968) 176-187
71. Shulman N. A mechanism of cell destruction in individuals sensitized to foreign antigens and its implications in auto-immunity. Combined clinical staff conference at the national institutes of health. Ann Intern Med 60 (1964) 506-521
72. Smith M.E., Reid D.M., Jones C.E., et al. Binding of quinine- and quinidine-dependent drug antibodies to platelets is mediated by the Fab domain of the immunoglobulin G and is not Fc dependent. J Clin Invest 79 (1987) 912-917
73. Amiral J., Bridey F., Dreyfus M., et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 68 (1992) 95-96
74. Visentin G.P., Ford S.E., Scott J.P., et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 93 (1994) 81-88
75. Greinacher A., Potzsch B., Amiral J., et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 71 (1994) 247-251
76. Kelton J.G., Smith J.W., Warkentin T.E., et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 83 (1994) 3232-3239
77. Visentin G.P. Heparin-induced thrombocytopenia: molecular pathogenesis. Thromb Haemost 82 (1999) 448-456
78. Warkentin T.E., Levine M.N., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332 (1995) 1330-1335
79. Warkentin T.E. An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost 30 (2004) 273-283
80. Visentin G.P., Wolfmeyer K., Newman P.J., et al. Detection of drug-dependent, platelet-reactive antibodies by antigen-capture ELISA and flow cytometry. Transfusion 30 (1990) 694-700
81. McFarland J.G. Laboratory investigation of drug-induced immune thrombocytopenias. Transfus Med Rev 7 (1993) 275-287
82. Kiefel V. The MAIPA assay and its applications in immunohaematology. Transfus Med 2 (1992) 181-188
83. Kiefel V., Santoso S., Schmidt S., et al. Metabolite-specific (IgG) and drug-specific antibodies (IgG, IgM) in two cases of trimethoprim-sulfamethoxazole-induced immune thrombocytopenia. Transfusion 27 (1987) 262-265
84. Mueller-Eckhardt C., and Salama A. Drug-induced immune cytopenias: a unifying pathogenetic concept with special emphasis on the role of drug metabolites. Transfus Med Rev 4 (1990) 69-77
85. Bougie D., Johnson S.T., Weitekamp L.A., et al. Sensitivity to a metabolite of diclofenac as a cause of acute immune hemolytic anemia. Blood 90 (1997) 407-413
86. Claas F.H., Langerak J., de Beer L.L., et al. Drug-induced antibodies: interaction of the drug with a polymorphic platelet-antigen. Tissue Antigens 17 (1981) 64-66